Related Experiment Video

Updated: Dec 29, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.7K

New Treatment Options for Advanced Gastroesophageal Tumours: Mature for the Current Practice?

Hannah Christina Puhr1,2, Matthias Preusser1,2, Gerald Prager1,2

  • 1Department of Medicine I, Division of Oncology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.

Cancers
|February 5, 2020
PubMed

Insights

Novel immunotherapy agents show promise for advanced gastroesophageal tumors, leading to approvals in later treatment lines. Targeted therapies have yielded disappointing results in clinical trials for these difficult-to-treat cancers.

Area of Science:

  • Oncology
  • Gastroenterology
  • Clinical Trials

Background:

  • Advanced gastroesophageal tumors present significant treatment challenges.
  • Previous treatment lines have limited efficacy for these advanced cancers.

Purpose of the Study:

  • To review recent clinical trials for advanced gastroesophageal tumors.
  • To evaluate novel targeted therapies, immunotherapies, and chemotherapies.
  • To discuss the current impact and approval status of these agents.

Main Methods:

  • Systematic review of recent clinical trial data.
  • Analysis of treatment outcomes for novel agents.
  • Assessment of current regulatory approval status.

Main Results:

  • Immunotherapy agents demonstrate promising activity in second and third-line settings.
  • Targeted therapy regimens have shown largely disappointing results.
  • Chemotherapy remains a component of treatment strategies.

Conclusions:

  • Immunotherapy represents a significant advancement in treating advanced gastroesophageal tumors.
  • Treatment decisions should consider the efficacy and approval status of novel agents.
  • Further research is ongoing to optimize treatment for gastroesophageal cancers.
Keywords:
chemotherapygastric cancergastroesophageal cancerimmunotherapytargeted therapy

More Related Videos

Single Incision Plus One Port Laparoscopic Proximal Gastrectomy with Double Channel Anastomosis for Gastric Cancer Treatment03:32

Single Incision Plus One Port Laparoscopic Proximal Gastrectomy with Double Channel Anastomosis for Gastric Cancer Treatment

Published on: December 27, 2024

1.4K

Related Concept Videos

Barrett Esophagus-II: Clinical Manifestations and Management01:21

Barrett Esophagus-II: Clinical Manifestations and Management

Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
681
Gastroesophageal Reflux Disease II: Clinical Features and Management01:29

Gastroesophageal Reflux Disease II: Clinical Features and Management

Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
610
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding01:15

Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding

Enteral nutrition encompasses various methods of delivering nutrition directly to the gastrointestinal (GI) tract, bypassing traditional oral intake. It is particularly beneficial for patients who cannot eat by mouth but have a functioning digestive system. Key methods include nasointestinal feeding, gastrostomy, and jejunostomy, each suited to different clinical scenarios based on the patient's needs and condition.
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube...
688
Peptic Ulcer Disease V: Surgical Management and Nursing Care01:25

Peptic Ulcer Disease V: Surgical Management and Nursing Care

Surgical management and nursing care are crucial in treating Peptic Ulcer Disease (PUD). Here is an organized and enhanced overview of the surgical interventions and the associated nursing care for PUD:
Surgical Interventions for Peptic Ulcer Disease
740
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K